Human IGFBP-1 Protein, His Tag (MALS verified)
分子別名（Synonym）
IGFBP1,PP12,IBP1
表達區(qū)間及表達系統(tǒng)（Source）
Human IGFBP-1 Protein, His Tag (IG1-H52H3) is expressed from human 293 cells (HEK293). It contains AA Ala 26 - Asn 259 (Accession # P08833).
Predicted N-terminus: Ala 26
蛋白結(jié)構(gòu)（Molecular Characterization）
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 27.2 kDa. The protein migrates as 32-35 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method / rFC method.
純度（Purity）
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景介紹
Insulin-like growth factor-binding protein 1 (IGFBP1) is also known as placental protein 12 (PP12), which contains oneIGFBP N-terminal domain and one thyroglobulin type-1 domain. IGFBP1 can bindd both insulin-like growth factors (IGFs) I and II and circulates in the plasma. Binding of IGFBP1 can prolongd the half-life of the IGFs and alterd their interaction with cell surface receptors. Furthermore, IGFBP1 can promote cell migration. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.
關(guān)鍵字： IGFBP-1;IGFBP-1蛋白;IGFBP-1重組蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。